中国人群N-乙酰基转移酶2基因型分布特征及不同基因分型方法的比较

doi:10.19982/j.issn.1000-6621.20210737

摘要/Abstract

摘要：

目的: 分析中国人群N-乙酰基转移酶2(N-acetyltransferase-2,NAT2)基因型分布特征及不同基因分型方法的效能。 方法: 对包含中国人群NAT2基因多态性数据的文献进行检索,检索范围包括Medline、PubMed、Embase、维普中文科技期刊数据库、中国知网和万方医学网等数据库,检索时限为数据库建库至 2021年12月1日。英文检索词:NAT2、N-acetyltransferase、polymorphism、China或Chinese等;中文检索词:NAT2、基因多态性、中国等。使用Newcastle-Ottawa Scale(NOS)评分表对纳入的文献进行质量评价和风险评估。提取文献中NAT2基因型及等位基因信息,重建单项研究NAT2基因型数据库并利用Phase 2.1软件进行单体型和双体型重建及验证。构建中国人群NAT2基因型分布数据库,分析NAT2等位基因和基因型分布特点。基于构建的NAT2基因型数据库,评估不同NAT2基因型分型推断方法的效能。 结果: 经过文献检索及筛选,共有10项研究的结果纳入本研究。汇总纳入10项研究中对照组4010例个体的基因型数据,NAT2快代谢基因型、中间代谢基因型、慢代谢基因型总体频率分别为25.79%(1034/4010)、50.87%(2040/4010)、23.34%(936/4010),NAT2非慢代谢基因型总体频率为76.66%(3074/4010);NAT2快、慢代谢等位基因总体携带频率分别为51.19%(4096/8002)及48.81%(3906/8002)。3SNP法推断NAT2慢代谢基因型的敏感度和特异度分别为99.92%(1249/1250)和99.81%(4190/4198);推断NAT2快代谢基因型的敏感度和特异度分别为100.00%(1484/1484)和99.92%(3961/3964)。2SNP法推断NAT2慢代谢基因型的敏感度和特异度分别为99.52%(1194/1250)和98.36%(4129/4198);推断NAT2快代谢基因型的敏感度和特异度分别为93.19%(1383/1484)和96.01%(3806/3964)。3SNP法和2SNP法推断NAT2慢代谢基因型敏感度差异无统计学意义(χ²=0.189,P=0.664),一致性较好(Kappa=0.932)。3SNP法推断NAT2快代谢基因型敏感度优于2SNP法(χ²=10.973,P=0.001)。 结论: 我国人群NAT2代谢基因型以非慢代谢基因型为主,在中国人群中3SNP法推断NAT2基因型效能优于2SNP法。

关键词: 乙酰基转移酶类, 基因型, 等位基因, 人群监测, 中国

Abstract:

Objective: To analyze the distribution characteristics of N-acetyltransferase-2 (NAT2) genotypes and the effectiveness of different genotyping methods in Chinese population. Methods: The literatures containing NAT2 gene polymorphism data of Chinese population were retrieved in Medline, PubMed, Embase, China Science and Technology Journal Database, China National Knowledge Internet, and Wanfang database. The retrieval time limit was from the establishment of the database to December 1, 2021, with the English search words of NAT2, N-acetyltransferase, polymorphism, China or Chinese, etc., and Chinese search words of NAT2, gene polymorphism, China, etc.. Newcastle Ottawa scale (NOS) was used to evaluate the quality and bias risk of the included literature. The NAT2 genotype and allele data in the literature were extracted, the NAT2 genotype database of single study was reconstructed, and the haplotype and diplotype were reconstructed and verified by phase 2.1 software. The NAT2 genotype of the control group in the literature were extracted to construct the NAT2 genotype distribution database of Chinese population, and the distribution characteristics of NAT2 alleles and genotypes were analyzed. Based on the constructed NAT2 genotype database, the efficiency of different NAT2 genotyping panels was evaluated. Results: Through literature retrieval and screening, the results of 10 studies were included. The genotype data in the control group of 4010 individuals were summarized. The overall frequencies of NAT2 fast, intermediate and slow metabolism genotype were 25.79% (1034/4010), 50.87% (2040/4010) and 23.34% (936/4010), respectively, the total frequency of NAT2 non-slow metabolism genotype was 76.66% (3074/4010); the total frequencies of NAT2 fast and slow metabolism alleles were 51.19% (4096/8002) and 48.81% (3906/8002), respectively. Using 3SNP method, the sensitivity and specificity of NAT2 slow metabolism genotype inferring were 99.92% (1249/1250) and 99.81% (4190/4198), and were 100.00% (1484/1484) and 99.92% (3961/3964) in NAT2 fast metabolism genotype inferring. Using 2SNP method, the sensitivity and specificity of in NAT2 slow metabolism genotype inferring were 99.52% (1194/1250)and 98.36% (4129/4198); and in NAT2 fast metabolism genotype inferring were 93.19% (1383/1484) and 96.01% (3806/3964). There was no significant difference in the sensitivity of NAT2 slow metabolism genotypes inferred by 3SNP and 2SNP method (χ²=0.189, P=0.664), and there was high consistency between the two methods (Kappa=0.932). The sensitivity of 3SNP method in inferring of NAT2 fast metabolism genotype was higher than that of 2SNP method (χ²=10.973, P=0.001). Conclusion: Non-slow metabolic genotypes constitute the majority of NAT2 metabolic genotypes in Chinese population, and the efficiency of 3SNP method was better than 2SNP method in inferring of NAT2 genotypes.

Key words: Acetyltransferases, Genotype, Alleles, Population surveillance, China

中图分类号:

R968

王宁, 郑璐瑶, 孟秀娟, 刘海婷, 丁杨明, 姚蓉, 郭少晨, 陆宇. 中国人群N-乙酰基转移酶2基因型分布特征及不同基因分型方法的比较[J]. 中国防痨杂志, 2022, 44(6): 625-634. doi: 10.19982/j.issn.1000-6621.20210737

WANG Ning, ZHENG Lu-yao, MENG Xiu-juan, LIU Hai-ting, DING Yang-ming, YAO Rong, GUO Shao-chen, LU Yu. Distribution characteristics of N-acetyltransferase-2 genotypes and comparison methods of different genotyping in Chinese population[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 625-634. doi: 10.19982/j.issn.1000-6621.20210737

图/表 10

图1

表1

表2

表3

表4

纳入研究文献中NAT2等位基因分布情况

等位基因	分类	单体型	广州-2011	北京-2012	上海-2015	长沙-2006	上海-2012	郑州-2009	上海-2016	台北-2016	南宁-2021	上海-2004	合计
*4	R	CTCGAG	157(50.65)	128(59.81)	115(65.34)	178(45.18)	339(55.57)	251(59.20)	521(56.14)	412(55.98)	1737(43.58)	132(58.93)	3970(49.61)
*13	R	TTCGAG	0(0.00)	2(0.93)	3(1.70)	22(5.58)	9(1.48)	2(0.47)	2(0.22)	0(0.00)	66(1.66)	3(1.34)	109(1.36)
*11A	R	CTTGAG	0(0.00)	0(0.00)	0(0.00)	3(0.76)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	3(0.04)
*12A	R	CTCGGG	0(0.00)	4(1.87)	0(0.00)	0(0.00)	0(0.00)	3(0.71)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	7(0.09)
*12B	R	TTCGGG	0(0.00)	0(0.00)	0(0.00)	0(0.00)	4(0.66)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	4(0.05)
*12C	R	CTTGGG	0(0.00)	0(0.00)	0(0.00)	3(0.76)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	3(0.04)
*6A	S	TTCAAG	89(28.71)	34(15.89)	14(7.95)	78(19.80)	138(22.62)	87(20.52)	222(23.92)	184(25.00)	1264(31.71)	46(20.54)	2156(26.94)
*7B	S	TTCGAA	44(14.19)	36(16.82)	35(19.89)	70(17.77)	61(10.00)	63(14.86)	152(16.38)	117(15.90)	745(18.69)	38(16.96)	1361(17.01)
*5B	S	CCTGGG	15(4.84)	0(0.00)	2(1.14)	11(2.79)	21(3.44)	10(2.36)	30(3.23)	20(2.72)	174(4.37)	4(1.79)	287(3.59)
*6B	S	CTCAAG	0(0.00)	0(0.00)	1(0.57)	14(3.55)	32(5.25)	1(0.24)	0(0.00)	3(0.41)	0(0.00)	0(0.00)	51(0.64)
*7A	S	CTCGAA	0(0.00)	5(2.34)	0(0.00)	9(2.28)	6(0.98)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	20(0.25)
*5A	S	CCTGAG	2(0.65)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	7(1.65)	1(0.11)	0(0.00)	0(0.00)	0(0.00)	10(0.12)
*5C	S	CCCGGG	3(0.97)	0(0.00)	0(0.00)	2(0.51)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	5(0.06)
*5D	S	CCCGAG	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	1(0.45)	1(0.01)
*6J	S	TTCAAA	0(0.00)	1(0.47)	6(3.41)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	7(0.09)
*6N	S	TTTAAG	0(0.00)	0(0.00)	0(0.00)	4(1.02)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	4(0.05)
*10^a	S	CTCGAG	0(0.00)	2(0.93)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	2(0.02)
*19^a	S	CTCGAG	0(0.00)	2(0.93)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	0(0.00)	2(0.02)

表4

表5

表6

表7

表8

表9

参考文献 24

[1]	欧阳晓春, 刘振华. NAT2基因多态性与疾病遗传易感性的关系. 医学综述, 2006, 12(1): 20-21. doi: 10.3969/j.issn.1006-2084.2006.01.009. doi: 10.3969/j.issn.1006-2084.2006.01.009
[2]	Hein DW, Millner LM. Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy-a focused review. Expert Opin Drug Metab Toxicol, 2021, 17(1): 9-21. doi: 10.1080/17425255.2021.1840551. doi: 10.1080/17425255.2021.1840551 URL
[3]	陈亮亮, 胡文豪, 刘魁, 等. N-乙酰基转移酶2基因多态性与膀胱癌的易感性在亚洲人群中的Meta分析. 临床泌尿外科杂志, 2014, 29(2): 118-124. doi: 10.13201/j.issn.1001-1420.2014.02.009. doi: 10.13201/j.issn.1001-1420.2014.02.009
[4]	Chen HC, Cao YF, Hu WX, et al. Genetic polymorphisms of phase Ⅱ metabolic enzymes and lung cancer susceptibility in a population of Central South China. Dis Markers, 2006, 22(3): 141-152. doi: 10.1155/2006/436497. doi: 10.1155/2006/436497 URL
[5]	Quan L, Chattopadhyay K, Nelson HH, et al. Differential association for N-acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population. Oncotarget, 2016, 7(26): 40012-40024. doi: 10.18632/oncotarget.9475. doi: 10.18632/oncotarget.9475 pmid: 27223070
[6]	Bandmann O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet, 1997, 350(9085): 1136-1139. doi: 10.1016/s0140-6736(97)03495-8. doi: 10.1016/s0140-6736(97)03495-8 pmid: 9343502
[7]	Zhang M, Wang S, Wilffert B, et al. The association between the NAT 2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol, 2018, 84(12): 2747-2760. doi: 10.1111/bcp.13722. doi: 10.1111/bcp.13722 pmid: 30047605
[8]	首都医科大学附属北京胸科医院, 《中国防痨杂志》编辑委员会. 结核病患者N-乙酰基转移酶2编码基因多态性检测与异烟肼合理用药专家共识. 中国防痨杂志, 2021, 43(11): 1107-1112. doi: 10.3969/j.issn.1000-6621.2021.11.001. doi: 10.3969/j.issn.1000-6621.2021.11.001
[9]	Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT 2 activity. J Toxicol Environ Health B Crit Rev, 2009, 12(5/6): 440-472. doi: 10.1080/10937400903158383. doi: 10.1080/10937400903158383 URL
[10]	Lu JF, Cao XM, Liu ZH, et al. Genetic analysis of N-acetyltransferase polymorphism in a Chinese population. Acta Pharmacologica Sinica, 1998, 19(4): 347-351. doi: 10.1016/S0300-483X(98)00043-2. doi: 10.1016/S0300-483X(98)00043-2 pmid: 10375782
[11]	Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics, 2012, 13(1): 31-41. doi: 10.2217/pgs.11.122. doi: 10.2217/pgs.11.122 URL
[12]	Selinski S, Blaszkewicz M, Lehmann ML, et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics, 2011, 21(10): 673-678. doi: 10.1097/FPC.0b013e3283493a23. doi: 10.1097/FPC.0b013e3283493a23 URL
[13]	Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet, 2001, 68(4): 978-989. doi: 10.1086/319501. doi: 10.1086/319501 pmid: 11254454
[14]	Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet, 2005, 76(3): 449-462. doi: 10.1086/428594. doi: 10.1086/428594 pmid: 15700229
[15]	Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet, 2003, 73(5): 1162-1169. doi: 10.1086/379378. doi: 10.1086/379378 pmid: 14574645
[16]	An H, Wu XQ, Wang ZY, et al. NAT2 and CYP2E 1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol, 2012, 39(6): 535-543. doi: 10.1111/j.1440-1681.2012.05713.x. doi: 10.1111/j.1440-1681.2012.05713.x. URL
[17]	沈婷婷, 张琴, 张文宏, 等. 中国汉族结核病患者 N-乙酰基转移酶2基因型与药物性肝损伤以及抗结核疗效的关系. 中华传染病杂志, 2015, 33(6): 327-330. doi: 10.3760/cma.j.issn.1000-6680.2015.06.003. doi: 10.3760/cma.j.issn.1000-6680.2015.06.003
[18]	李昕洁, 王云南, 邹永红, 等. 155例汉族结核病患者N-乙酰基转移酶2(NAT2)基因多态性分析. 中国防痨杂志, 2011, 33(6): 357-360.
[19]	Song DK, Xing DL, Zhang LR, et al. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev, 2009, 32(5/6): 416-423. doi: 10.1016/j.cdp.2009.02.003. doi: 10.1016/j.cdp.2009.02.003 URL
[20]	Ma QW, Lin GF, Chen JG, et al. N-Acetyltransferase 2 genotype, exfoliated urothelial cells and benzidine exposure. Front Biosci (Elite Ed), 2012, 4(5): 1966-1974. doi: 10.2741/517. doi: 10.2741/517
[21]	Xie Q, Li H, Huang L, et al. N-Acetyltransferase 2 (NAT2) single nucleotide polymorphisms in patients with adult acute myeloid leukemia (NON-M3): A case-control study. Acta Medica Mediterranea, 2021, 37(4): 2449-2456. doi: 10.19193/0393-6384_2021_4_382. doi: 10.19193/0393-6384_2021_4_382
[22]	Guo WC, Lin GF, Zha YL, et al. N-Acetyltransferase 2 gene polymorphism in a group of senile dementia patients in Shanghai suburb. Acta Pharmacol Sin, 2004, 25(9): 1112-1117.
[23]	Chang CH, Huang YS, Perng CL, et al. N-Acetyltransferase 2 (NAT2) genetic variation and the susceptibility to noncardiac gastric adenocarcinoma in Taiwan. J Chin Med Assoc, 2016, 79(3): 105-110. doi: 10.1016/j.jcma.2015.08.011. doi: 10.1016/j.jcma.2015.08.011 URL
[24]	Shishikura K, Hohjoh H, Tokunaga K. Novel allele containing a 190C>T nonsynonymous substitution in the N-acetyltransferase (NAT2) gene. Hum Mutat, 2000, 15(6):581. doi: 10.1002/1098-1004(200006)15:6<581::AID-HUMU17>3.0.CO;2-V. doi: 10.1002/1098-1004(200006)15:6<581::AID-HUMU17>3.0.CO;2-V

发表时间	期刊	单位	研究对象数量	民族	人群构成	NAT2基因多态性检测方法	研究编号
2011年^[18]	中国防痨杂志	广州市胸科医院	155	汉族	结核病患者	PCR测序	广州-2011
2012年^[16]	Clinical and Experimental Pharmacology and Physiology	解放军第309医院	208	不明确	结核病患者	PCR测序	北京-2012
2006年^[4]	Disease Markers	中南大学附属湘雅医院	294	汉族	肺癌患者及健康对照者	PCR-RFLP	长沙-2006
2012年^[20]	Frontiers in Bioscience (Elite edition)	中国科学院上海分院及上海市疾病预防控制中心	336^a	汉族	膀胱癌患者及健康对照者	PCR-RFLP	上海-2012
2015年^[17]	中华传染病杂志	复旦大学附属华山医院和上海交通大学医学院附属同仁医院	108	汉族	结核病患者	PCR测序	上海-2015
2016年^[5]	Oncotarget	华南理工大学等	951^b	不明确	膀胱癌患者及健康对照者	iPLEX Gold Assay	上海-2016
2016年^[23]	Journal of the Chinese Medical Association	中国台湾台北荣民总医院	736	不明确	胃癌患者及健康对照者	SNP特异性PCR	台北-2016
2009年^[19]	Cancer Detection and Prevention	郑州大学第一附属医院	420	汉族	膀胱癌患者及健康对照者	PCR-RFLP	郑州-2009
2021年^[21]	Acta Medica Mediterranea	广西医科大学第一附属医院等	2091	汉族	急性髓系白血病(非M3)患者及健康对照者	SNaPshot	南宁-2021
2004年^[22]	Acta Pharmacologica Sinica	中国科学院上海分院等	163	汉族	老年性痴呆患者及健康对照者	PCR-RFLP	上海-2004

研究编号	研究对象选择	组间可比性	暴露因素测量
广州-2011^a	-	-	-
北京-2012	★★★	★	★★★
长沙-2006	★★★★	★★	★★★
上海-2012	★★★★	★	★★
上海-2015	★★★	-	★★★
上海-2016	★★★★	★	★★★
台北-2016	★★★	★★	★★
郑州-2009	★★★★	★★	★★★
南宁-2021	★★★	★	★★★
上海-2004	★★★★	★	★★★

研究编号	NAT2快代谢基因型	NAT2中间代谢基因型	NAT2慢代谢基因型	合计
广州-2011	36(23.3)	85(54.8)	34(21.9)	155
北京-2012	40(37.4)	54(50.5)	13(12.1)	107
长沙-2006	47(23.9)	112(56.9)	38(19.2)	197
上海-2012	102(33.4)	148(48.5)	55(18.1)	305
上海-2015	36(40.9)	46(52.3)	6(6.8)	88
上海-2016	137(29.0)	258(54.5)^a	78(16.5)	473
上海-2004	37(33.0)	61(54.5)	14(12.5)	112
郑州-2009	72(34.0)	112(52.8)	28(13.2)	212
台北-2016	108(29.3)	199(54.1)	61(16.6)	368
南宁-2021	419(21.0)	965(48.4)	609(30.6)	1993
合计	1034(25.8)	2040(50.9)	936(23.3)	4010

基因型	频数	NAT2实际基因型	6SNP位点多态性	3SNP法推断基因型	2SNP法推断基因型
4/4	1366	R	CC TT CC GG AA GG	R	R
4/12A	13	R	CC TT CC GG AG GG	R	R
4/12B	3	R	CT TT CC GG AG GG	R	I
4/13A	88	R	CT TT CC GG AA GG	R	I
13A/13A	10	R	TT TT CC GG AA GG	R	S
4/11A	4	R	CC TT CT GG AA GG	R	R
4/5A	6	I	CC CT CT GG AA GG	I	I
4/5B	178	I	CC CT CT GG AG GG	I	I
4/5C	6	I	CC CT CC GG AG GG	I	I
4/5D	1	I	CC CT CC GG AA GG	I	I
4/6A	1452	I	CT TT CC AG AA GG	I	I
4/6B	139	I	CC TT CC AG AA GG	I	R
4/6J	8	I	CT TT CC AG AA AG	S	I
4/6N	1	I	CT TT CT AG AA GG	I	I
4/7A	7	I	CC TT CC GG AA AG	I	R
4/7B	838	I	CT TT CC GG AA AG	I	I
基因型	频数	NAT2实际基因型	6SNP位点多态性	3SNP法推断基因型	2SNP法推断基因型
4/10	2	I	CC TT CC GG AA GG	R	R
4/19	1	I	CC TT CC GG AA GG	R	R
6A/11	1	I	CT TT CT AG AA GG	I	I
7A/11A	2	I	CC TT CT GG AA AG	I	R
7A/12B	4	I	CT TT CC GG AG AG	I	I
7A/13A	2	I	CT TT CC GG AA AG	I	I
6A/13	35	I	TT TT CC AG AA GG	I	S
6A/12A	3	I	CT TT CC AG AG GG	I	I
7B/13	18	I	TT TT CC GG AA AG	I	S
5B/13	4	I	CT CT CT GG AG GG	I	S
7B/12C	3	I	CT TT CT GG AG AG	I	I
13/6N	2	I	TT TT CT AG AA GG	I	S
11A/6N	1	I	CT TT TT AG AA GG	I	I
5A/5B	9	S	CC CC TT GG AG GG	S	S
5A/6A	6	S	CT CT CT AG AA GG	S	S
5B/5B	9	S	CC CC TT GG GG GG	S	S
5B/6A	93	S	CT CT CT AG AG GG	S	S
5B/7B	70	S	CT CT CT GG AG AG	S	S
5C/6A	1	S	CT CT CC AG AG GG	S	S
6A/6A	374	S	TT TT CC AA AA GG	S	S
6A/6B	38	S	CT TT CC AA AA GG	S	I
6A/7B	482	S	TT TT CC AG AA AG	S	S
6A/19	1	S	CT TT CC AG AA GG	I	I
6B/6B	2	S	CC TT CC AA AA GG	S	R
6B/7A	4	S	CC TT CC AG AA AG	S	R
6B/7B	4	S	CT TT CC AG AA AG	S	I
6J/7B	1	S	TT TT CC AG AA AA	S	S
7A/7A	1	S	CC TT CC GG AA AA	S	R
7A/7B	6	S	CT TT CC GG AA AA	S	I
7B/7B	149	S	TT TT CC GG AA AA	S	S

3SNP法推断	NAT2基因型频数		敏感度 (%)	特异度 (%)	阳性预测值 (%)	阳性预测值 (%)	准确度 (%)
3SNP法推断	S	R+I	敏感度 (%)	特异度 (%)	阳性预测值 (%)	阳性预测值 (%)	准确度 (%)
S	1249	8	99.92	99.81	99.36	99.98	99.83
R+I	1	4190
合计	1250	4198